Association of the +936 C/T Single Nucleotide Polymorphism of the VEGF-A Gene with Renal Cell Cancer in an Eastern Indian Population

Main Article Content

Anindya Dasgupta
Subhrajyoti Dasgupta
Debabrata Samanta
Angshuman Ashu
Dilip Karmakar

Abstract

Aims: Renal cell cancer is one of the major killer cancers affecting mankind. Various polymorphisms in different genes have been found to be associated with the disease. +936 C/T SNP in the VEGF gene has been reported to be associated with spread of metastasis in several parts of the world. In the present study, we decided to study its association with renal cell cancer in the Eastern Indian population.

Study Design: A hospital based cross sectional study.

Place and Duration of Study: A tertiary care medical college & hospital in Kolkata, West Bengal having study duration of one year from January 2018 to January 2019.

Methodology: DNA was extracted from whole blood using phenol chloroform extraction method from 30 case and 40 control subjects. A section of the VEGF-A gene consisting of the base pair where the SNP occurs and small regions adjacent to it was then amplified from the genomic DNA by PCR. The PCR product was treated with restriction enzyme HinDIII and the restriction digestion pattern was analysed.

Results: In our results, the prevalence of the wild C and the mutant T alleles in the study group were found to be 60% and 40% respectively. The prevalence of the homozygous non-mutant (CC), heterozygous (CT) and the homozygous mutant (TT) genotypes were found to be 45%, 30% and 25% respectively.

Conclusion: It is likely that there is a significant association between the +936 C/T SNP and renal cell cancer in the Eastern Indian population. Also, majority of the renal cell cancer patients from this region are prone to worse cancer prognosis and therefore may need a more active medical management including anti VEGF therapy. Further studies are required to confirm the association and to determine its nature.

Keywords:
Renal cancer, VEG, single nucleotide polymorphis, polymerase chain reaction, restriction fragment length polymorphism, 936 C/T SNP of VEGF gene.

Article Details

How to Cite
Dasgupta, A., Dasgupta, S., Samanta, D., Ashu, A., & Karmakar, D. (2019). Association of the +936 C/T Single Nucleotide Polymorphism of the VEGF-A Gene with Renal Cell Cancer in an Eastern Indian Population. Journal of Advances in Medicine and Medical Research, 31(7), 1-7. https://doi.org/10.9734/jammr/2019/v31i730306
Section
Original Research Article

References

Galligioni E, Ferro A. Angiogenesis and antiangiogenic agents in non-small cell lung cancer. Lung Cancer. 2001; 34(Suppl 4):S3-7.

Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-57.

Gong M, et al. Vascular endothelial growth factor gene polymorphisms and the risk of renal cell carcinoma: Evidence from eight case-control studies. Oncotarget. 2017;8(5):8447-8458.

Dassoulas K, et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis and survival. Mol Carcinog. 2009;48(6):563-9.

Jin Q, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 2005;11(10):3647-53.

Langsenlehner T, et al. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur J Cancer. 2008;44(11):1572-6.

Rani J, et al. Association of vascular endothelial growth factor single nucleotide polymorphisms on the prognosis of breast cancer patients. Indian J Cancer. 2014;51(4):512-7.

Neufeld G, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13(1):9-22.

Rosen LS. VEGF-targeted therapy: Therapeutic potential and recent advances. Oncologist. 2005;10(6):382-91.

Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-76.

Kawai Y, et al. Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol. 2007;52(4):1147- 55.

Abe A, et al. Single nucleotide polymorphisms in the 3 & prime; untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma. The Tohoku Journal of Experimental Medicine. 2002;181-190.

Bruyere F, et al. VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma. J Urol. 2010;184(4):1273-8.

Jannuzzi AT, et al. VEGF gene polymorphisms and susceptibility to colorectal cancer. Genet Test Mol Biomarkers. 2015;19(3):133-7.

Maltese P, et al. VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. Int J Colorectal Dis. 2009;24(2):165-70.

Kapahi R, et al. Association of VEGF and VEGFR1 polymorphisms with breast cancer risk in North Indians. Tumour Biol. 2015;36(6):4223-34.

Rezaei M, et al. Association between vascular endothelial growth factor gene polymorphisms with breast cancer risk in an Iranian population. Breast Cancer: Basic and Clinical Research. 2016;10:85-91.

Fan J, et al. Vascular endothelial growth factor polymorphisms and lung cancer risk. International Journal of Clinical and Experimental Medicine. 2015;8(4):6406-6411.

Tang J, et al. Association between vascular endothelial growth factor gene polymorphisms and the risk and prognosis of renal cell carcinoma: A systematic review and meta-analysis. Oncotarget. 2017;8(30):50034-50050.